Market News
Stay updated with the latest market trends, earnings, and economic indicators.
August MSCI Rejig Could Trigger Over Rs 30,000 Crore Inflows Into India; Laurus Labs, Biocon Lead Race
Among the likely beneficiaries, Laurus Labs and Biocon have been assigned a high probability of moving from the MSCI India Small Cap Index to the MSCI India Standard Index.
Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1
Biocon, currently the third-largest insulin supplier by volume, has invested “big time” in ramping up production capacity, Chairperson Kiran Mazumdar-Shaw says.
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon
Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalizing on growing demand as major pharmaceutical companies shift focus to newer weight-loss drugs. Currently the third-largest global insulin provider, Biocon is significantly expanding production. This strategic move addresses a critical gap in the market, particularly in emerging economies.
Insider trading: Supreme Court upholds SAT clearance to Biocon MD
The Supreme Court has backed a tribunal's decision, clearing Biocon's managing director, Shreehas P Tambe, of insider trading allegations from 2017. The Securities and Exchange Board of India's appeal was rejected. Tambe was accused of trading Biocon shares while possessing unpublished price-sensitive information.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.
Biocon Ltd spurts 2.76%, rises for fifth straight session
Biocon Ltd is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The stock is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma.
Five Stocks To Buy: ONGC, NTPC Green, Biocon And More | May 14, 2026
Top picks include bullish setups in ONGC, NTPC Green Energy, South West Pinnacle, Amber Enterprises, and Biocon.
Biocon soars 10% in 3 days, stock nears 52-week high; here's why
In the past 12 trading days, the market price of Biocon has appreciated by 20 per cent from a level of ₹349.65 on the BSE on April 24, 2026.
Biocon Ltd spurts 3.7%, gains for third straight session
Biocon Ltd is quoting at Rs 417.35, up 3.7% on the day as on 12:49 IST on the NSE. The stock is up 23.4% in last one year as compared to a 4.86% fall in NIFTY and a 11.37% fall in the Nifty Pharma index.
Technical stock picks! 3 shares that could give up to 15% return this May. Do you own any?
Following a recent downtrend, the Nifty has seen a rally, with analysts suggesting a buy-on-dips strategy. Three technical stock picks from Axis—KEI Industries, Grasim Industries, and Biocon—are highlighted, each with potential upside returns of up to 15% for May.
Tata Consumer among 5 F&O stocks with a sharp rise in futures open interest
Five NSE F&O stocks, Dalmia Bharat, Tata Consumer Products, Kaynes Technology India, Bharti Airtel and Biocon, recorded sharp futures open interest gains on May 11, signalling increased trader participation and fresh positioning activity.